Literature DB >> 12864764

Safety of a patented special butterbur root extract for migraine prevention.

Ulrich Danesch1, Reiner Rittinghausen.   

Abstract

OBJECTIVE: To report on the safety of a patented special butterbur root extract used for migraine prevention.
BACKGROUND: Two placebo-controlled clinical trials have been conducted supporting the beneficial use in humans.
METHODS: Results from acute, subchronic and chronic animal toxicity studies as well as from mutagenicity studies are reported. Safety data gained from clinical trials, postmarketing surveillance studies and pharmacovigilance are evaluated and discussed.
CONCLUSION: The patented special butterbur root extract is safe for the treatment in humans.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12864764     DOI： 10.1046/j.1526-4610.2003.03015.x

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


  7 in total

Review 1.  Current and investigational drugs for the prevention of migraine in adults and children.

Authors:  Frederick G Freitag; Derrick Shumate
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

2.  The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel.

Authors:  Silvia Benemei; Francesco De Logu; Simone Li Puma; Ilaria Maddalena Marone; Elisabetta Coppi; Filippo Ugolini; Wolfgang Liedtke; Federica Pollastro; Giovanni Appendino; Pierangelo Geppetti; Serena Materazzi; Romina Nassini
Journal:  Br J Pharmacol       Date:  2017-07-20       Impact factor: 8.739

3.  A novel petasin-modified zinc oxide eugenol sealer.

Authors:  Selvanathan M J Vinola; Kittappa Karthikeyan; Sekar Mahalaxmi
Journal:  J Conserv Dent       Date:  2020-08-04

Review 4.  The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review.

Authors:  Serena L Orr
Journal:  Curr Pain Headache Rep       Date:  2018-04-04

Review 5.  Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG).

Authors:  Gunther Haag; Hans-Christoph Diener; Arne May; Christian Meyer; Hartmut Morck; Andreas Straube; Peter Wessely; Stefan Evers
Journal:  J Headache Pain       Date:  2010-12-23       Impact factor: 7.277

6.  Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels.

Authors:  Johanna Kleeberg-Hartmann; Birgit Vogler; Karl Messlinger
Journal:  J Headache Pain       Date:  2021-04-13       Impact factor: 7.277

Review 7.  Evidence-Based Treatments for Adults with Migraine.

Authors:  Rubesh Gooriah; Randa Nimeri; Fayyaz Ahmed
Journal:  Pain Res Treat       Date:  2015-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.